Welcome to our dedicated page for MAIA Biotechnology news (Ticker: MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology stock.
MAIA Biotechnology, Inc. develops targeted immunotherapies for cancer, with news centered on its lead investigational therapy, ateganosine, also known as THIO, for non-small cell lung cancer. Company updates frequently address the THIO-101 clinical program, ateganosine’s telomere-targeting and immune-activating mechanism, use with the checkpoint inhibitor cemiplimab, and FDA Fast Track designation in third-line NSCLC.
Recurring MAIA news also includes oncology data presentations, shareholder letters on the development pipeline, clinical-site and trial-expansion updates, and financing activity tied to its clinical programs. Capital-market announcements have included common stock offerings, shelf registration use, and stated uses of proceeds for clinical trials, working capital, and general corporate purposes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
MAIA Biotechnology (NYSE American: MAIA) has reported promising updates on disease control data in the Part A safety lead-in of its ongoing THIO-101 phase 2 trial. The trial is evaluating THIO in sequential combination with cemiplimab for patients with advanced Non-Small Cell Lung Cancer (NSCLC) who have previously failed 2 or more prior lines of treatment.
Key findings include:
- 82% disease control rate: 9 out of 11 patients with post-baseline scans met the primary endpoint of disease control
- Disease control is defined as Complete Response, Partial Response, or Stable Disease per RECIST 1.1
- All patients had previously failed immune checkpoint inhibitor (CPI) and platinum-based chemotherapy treatments
- No new safety analysis was conducted at this time
The company's CEO, Vlad Vitoc, expressed encouragement with these preliminary results, noting that they align with pre-clinical data showing THIO's potential to enhance CPI effectiveness in resistant cases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.